Introduction
Changes in drug disposition properties caused by liver disease complicate drug selection and therapy management. Recent advances in computational biology are providing new, broadly applicable strategies to unravel such complexities. How does cirrhosis (Hung et al., 2002a,b) cause observed changes in hepatic drug disposition? More detailed understanding of precisely how drugs behave in diseased relative to normal livers requires new modeling strategies in which events at different levels can be observed and measured in both space and time. We address this need and provide a novel means of creating and testing real, working representations of hypothesized mechanisms. We present and validate a plausible explanation for structural and functional differences in the normal and diseased rat livers from the perspective of a specific drug, diltiazem (Hung et al., 2001) , a cationic compound known to interact with hepatic components at all levels. We then show how those changes may have caused the observed differences in diltiazem's disposition.
The In Silico Liver (ISL) , (Yan et al., 2008a,b) in Fig. 1 is an abstract analogue built in software using discrete, object-oriented methods. It is an advanced example of what has been referred to as executable biology (Fisher and Henzinger 2007) , . ISLs are physiologically based, multi-level analogues of livers undergoing perfusion. They are not intended to be accurate, precise descriptions of how we think the liver works nor are they intended to provide precise, accurate predictions. Rather, they help us reduce uncertainties about hepatic mechanisms enabling us to refine, explore, and test hypotheses about the mechanistic details of hepatic drug disposition. In depicting 3D hepatic morphology at a cellular level, it uses quasi-autonomous components that recognize and interact uniquely with mobile objects representing different compounds. The consequences of simulated local interactions and systemic phenomena are measured and studied simultaneously, analogous to how wet-lab experiments are conducted. Objects represent aspects of hepatic organization and function.
Drugs are represented using customizable, mobile objects: more than one drug can be studied simultaneously.
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When outflow profiles resulting from ISL execution are made experimentally indistinguishable from the actual profiles obtained from experiments using perfused normal or diseased livers, we can argue that the causative, mechanistic details occurring during ISL execution may have hepatic counterparts as diagrammed in Fig. 2A . Differences in mechanistic details (assembled components and how they interact with drugs) between the normal and "diseased" ISLs stand as hypotheses about differences between the normal and diseased livers. Execution of the two analogues tests that hypothesis. Having ISL profiles match referent, wet-lab profiles is evidence supporting those hypotheses. The differences in dynamic, multi-level details during execution of the two ISL types provide a plausible, physiologically based explanation of the disease-caused differences in hepatic drug disposition.
ISLs have been iteratively refined to achieve a rigorous degree of pre-specified similarity with referent outflow profiles. Starting with the same ISL used by (Yan et al., 2008a,b) , we accomplished two tasks. First, using a protocol of iterative refinement, we discovered two different parameterizations of a common ISL structure. When dosed with objects representing diltiazem, ISL outflow profiles adequately matched profiles from the normal and diseased livers reported in (Hung et al., 2002a) . Next, we designed and implemented methods to trace specific mechanistic events during ISL execution. We used derived measures of those events at different levels of detail to provide plausible explanations of how and why disposition differed between normal and diseased livers. We posit that aspects of those explanations have hepatological counterparts. Six ISL levels were studied: lobule, sinusoidal network, lobular zones, sinusoidal segments, cellular spaces, and intracellular contents. Traced simulation events included compounds interacting with lobular microarchitecture, cells, and intracellular factors that bind, sequester, and metabolize diltiazem. We simulated how compound may move to and through acinar spaces and provided measures of changes in local effects that may have been caused by disease. The results provide heretofore-unavailable views of how and where hepatic disposition of diltiazem and sucrose (Hung et al., 2001 ) may differ in normal and diseased rat livers. It provides a means of predicting plausible disposition properties in a diseased liver given a corresponding profile from a normal liver.
To date, mechanistic features of explanations encountered in the literature have not been testable:
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Because the methods are extensible to whole organisms and, eventually, patients, they open a door to new experimental means of testing the plausibility of such mechanistic explanations, and that, in turn, is expected to facilitate translation of research results to benefit patients.
Methods
In situ liver perfusion studies. Full details of the original single-pass perfusion experiments are provided in (Hung et al., 2002a,b) . Included are detailed descriptions of the established, carbon tetrachloride (CCl 4 ) treatment protocol. It was used on 150g male Wistar rats to induce acute hepatocellular injury thus providing a rat model of fibrotic, hepatic cirrhosis. Control PK profiles referred to as normal were obtained using livers from matched rats treated identically, absent CCl 4 . Several histopathology measures of both CCl 4 -treated and control livers characterized the nature and extent of disease. Diltiazem was one of several compounds studied. Six diltiazem outflow profiles were analyzed individually using established PK methods. The referent profile used in this study is the one presented in Fig. 1 of (Hung et al., 2002a) .
In Silico Liver and its framework. Classical physiologically based pharmacokinetic (PK) modeling (Hung et al., 2001) , (Hung et al., 2002a) and the approach used herein present different yet complementary approaches to exploring explanations of experimental data. The former provides a "black box" global description of flow, influx, efflux, binding, sequestration, and metabolism in the liver, and relates the resulting parameters conceptually to observed changes in liver pathophysiology and biochemistry. In contrast, ISLs use actual mechanisms-events occurring within precise spaces-in a manner that is more consistent with the actual intralobular arrangements, normal and pathological, than is possible with traditional mathematical models. Explanations of precisely how models of the ISL class differ from traditional physiologically based PK models are provided in the supplement to . For convenience, the Appendix contains definitions for cellular automata, agent-based, and agentThis article has not been copyedited and formatted. The final version may differ from this version. 
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Detailed descriptions of ISL design considerations, including the mappings between ISL components and mechanisms and liver histology and physiology are available in , (Yan et al., 2008a ). An abridged description follows. Additional detail is provided under Results. Because the relationship between ISL spaces, components, mechanisms, and phenomena-mappings A, B, and C in Fig. 2A -can be made increasingly realistic and similar to hepatic counterparts, we use analogue when referring to ISLs and their components to emphasize that they are fundamentally different from traditional PK models. A traditional PK model is a conceptual generalization. Because our knowledge of hepatology is far from complete, neither the model nor its parameters can be made realistic and similar to hepatic features (Rescigno, 2001 ). Development and validation of models of the ISL class has just begun.
Consequently, we are cautious in making claims about how faithfully ISL mechanisms represent actual normal or diseased mechanisms (mapping C in Fig. 2A ). At this stage, the mechanistic details presented are only plausible approximations of what actually occurred. To avoid conflating (in our own minds) ISL details with the biology, and to clearly distinguish in silico components and processes from corresponding hepatic structures and processes, hereafter we use SMALL CAPS when referring to the ISL counterparts.
The ISL is a simulation framework: an in silico counterpart to an entire wet-lab experimental system (analytical instrumentation and all). It comprises an experiment agent (defined in the Appendix), which is a highly abstract analogue of the scientists conducting liver perfusion experiments, a data management module, a statistical observer module that is used to analyze data, a parameter manager, and three different liver models: DatModel, RefModel, and ArtModel. DatModel represents referent data from in situ perfusion experiments (Hung et al., 2002a) . RefModel is a parameterized, classical PK model, the extended convection-dispersion model (Roberts and Anissimov, 1999) , which was previously fit to referent outflow profiles. ArtModel is the complete system illustrated in Fig. 1 . Because two ArtModel variants (NORMAL and DISEASED) are this paper's focus, hereafter one Monte Carlo variant of ArtModel is called a LOBULE. We assumed that anatomical, physiological, and PK characteristics of all normal hepatic lobules are similar Each LOBULE is an abstraction: it is not intended to be an accurate, precise description of hepatic physiology nor is it intended to provide precise, accurate predictions. Rather, experiments on it help reduce uncertainties about hepatic mechanisms by refining, exploring, and testing hypotheses about mechanistic details during hepatic drug disposition. Software objects represent spatial aspects of hepatic organization and function. The consequences following executions are measured and studied simultaneously, analogous to how wet-lab experiments are conducted. Studies of ISL mechanisms during execution are expected to improve insight into the details of hepatic drug disposition in much the same way that study of interactions of drugs and hepatocytes in cultures can provide translatable insight into the hepatic disposition of drugs in whole organisms.
The LOBULE component. A LOBULE is a stand-alone software device. It includes components designed to mimic targeted lobular anatomical and physiological attributes believed to play roles influencing the disposition and clearance of drugs (Fig. 2) . LOBULE components can be modified and plugged together in different ways as needed to represent different lobular properties .
A principle guiding LOBULE and LIVER development has been that when measures of its behaviors are indistinguishable experimentally from referent wet-lab data, using some quantitative comparison (mapping A in Fig. 2A ), then the ISL mechanisms and events may have hepatic counterparts (mappings B and C in Fig. 2A ). The acceptability of such a mapping increases when each LOBULE component maps logically to identifiable hepatic components. Another guiding principle has been that, because any LOBULE component can be easily replaced by a more complicated component when that extra detail is needed, a LOBULE and thus a LIVER should be no more complicated than is needed to achieve the stated objective. A LOBULE has the six levels illustrated in Fig. 1 A network of Sinusoidal Segments. A software agent (an autonomous object that schedules its own events and interacts with other agents and objects in its environment; see Appendix for related information) called a Sinusoidal Segment (SS) represents all aspects of sinusoid function that influence drug disposition. Each SS is somewhat different and the stochastic differences are parameter controlled.
A graph edge specifies a connection between two SSs. The SINUSOID network is subdivided into three zones. Zone I, being close to PV, always has more nodes; Zone III, being next to CV, has the fewest.
SSs per zone were Zone I = 45, Zone II = 20, and Zone III = 5. As explained in , that number was needed to have sufficient PV-to-CV path variety to reduce fluctuations within outflow profiles. They were connected using 109 edges: 39 intra-Zone I edges, 8 intra-Zone II connections (but no intra-Zone III connections), 37 Zone I-to-Zone II, and 25 Zone II-to-Zone III connections. All Zone III nodes were connected to CV. There were two constraints: no self-self edges and no two-node cycles (a restriction that was not imposed in and (Yan et al., 2008a,b) ), and if any node was, by chance, not assigned an outgoing edge, it was connected directly to CV. Two SS types were used: direct (larger, shorter) and tortuous (thinner, longer).
Each SS consists of a Core surrounded by three identically-sized spaces. The Core represents blood flow. Space A represents the interface between vascular flow and the endothelial layer. Space B is called the ENDOTHELIAL layer. It represents the most easily accessible spaces and cells, primarily endothelial cells and fenestra. Space C represents less accessible spaces and cells, primarily the space of Disse, hepatocytes, and bile canaliculi. A Bile Space, illustrated in Fig. 1 , can be made available when needed, but it was not needed for this study of unchanged diltiazem. Parameters allow the resolution of the spaces to be increased (or decreased) as needed. In this study, space size was the same as in and (Yan et al., 2008a,b CELLS contain objects that represent required intracellular components and processes, including drug binding, metabolism, transport, and sequestration. Because the in situ perfusions had short durations (less than one hour), we assumed that cell biology and biochemistry were relatively constant. Consequently, those details have been abstracted away, but can be added easily when needed without having to reengineer ISLs. The only intracellular events that are important for studying the disposition kinetics of unchanged dilitiazem were its binding, sequestration, and metabolism. However, disease can affect the intracellular hepatic transport kinetics (Hung et al, 2005a ) and biliary clearance (Hung et al., 2005b ) of other compounds, with biliary clearance being more likely when the solutes are large and polar (Roberts et al, 2002) . As some of the polar diltiazem metabolites are cleared into the bile (Sugawara et al., 1988) , the bile space is shown in the model (Fig. 1) . Even though it is known that basic compounds are sequestered in organelles such as lysosomes and mitochondria, as well as being bound in hepatocytes (Hung et al., 2002a) , (Siebert et al., 2004) , motivated by parsimony, sequestration and binding were not resolved: drug molecules within cells are simply subdivided and represented as being in one of three states: free to exit (partition out), bound, or unbound and freely moving. Everything within a cell that can bind or sequester diltiazem was conflated and represented by some number of identical binding objects In silico liver parameters. The LIVER and its components from (Yan et al., 2008a,b) were re-used This article has not been copyedited and formatted. The final version may differ from this version. for this study. See (Yan et al., 2008a) and the supplemental data for a full list of parameter names, descriptions, and values (see Supplemental Table S1 ). For convenience, several key parameters are listed in Table 1 and the specifics of others important to this report are discussed below and under Results. This class of synthetic, executable models was developed in part to explore and test hypotheses about biological mechanisms. An objective of this study has been to explore alternative mechanistic explanations and offer one that validates and so may account for the differences in outflow profiles of diltiazem administered to normal and diseased livers. The histopathology data showed that within the CCl 4 -treated livers, significant cirrhotic change occurred at cellular and subcellular levels (Hung et al., 2002a,b) . Microscopy evidence also showed that microvascular and microcirculation changes occurred (Gaudio et al., 1997) . For simplicity, many of the details known about liver fibrosis, including the principal role played by hepatic stellate cells, for example, were not added to the list of targeted attributes.
It is tempting to assume that those visible changes must have contributed in important ways to the observed alterations in outflow profiles. Yet, we do not know the dispositional significance of such changes for specific compounds. We elected to make no inferences but seek one of the simpler sets of changes that could provide a plausible explanation. It may be possible, for example, that two different SINUSOID networks, with all cellular and subcellular details being unchanged, can provide an explanation for the differences. However, Hung et al. showed significant correlations between measures of histopathology and changed PK parameter values. We therefore elected to begin by re-using the validated NORMAL LIVER SINUSOID network, once identified, for the DISEASED LIVERS. We then looked for explanatory change at the SS level and below.
Discovering differences between NORMAL and DISEASED LIVERS. The approach taken followed three steps. First, we identified a parameterized LIVER that would validate against the diltiazem outflow profile from the normal liver with a Similarity Measure (SM) value, discussed below, > 0.8. Second, we identified a subset of parameters to be changed, and then sought focused changes in SS component parameterizations that would alter the outflow profile in ways consistent with the referent diseased outflow profile. We identified a subset of parameters for change, and then tested the hypothesis that a new valuation of the subset, in combination with unchanged values of all other parameters, would yield a LIVER that could achieve the minimally acceptable SM > 0.8. When unsuccessful, we returned to step two. Third, we fine-tuned that candidate NORMAL LIVER and then the DISEASED LIVER parameter vectors with the objective of achieving SM > 0.9 (within a factor of 0.33 of the referent value, as discussed below). When unsuccessful, we returned to step one or two.
Discovering a parameterized, NORMAL LIVER that would validate followed a similar, iterative refinement process. We reported earlier that because the emergent influence of parameters on dynamic ISL attributes is highly networked, more than one parameter vector could give essentially indistinguishable outflow profiles. Although every effort was made to construct a minimal model, the requirement that LOBULAR structures be derived or inferred from published hepatic knowledge rather than induced from particular data sets provides some complexity and overlapping phenomena.
Such complexity, natural to constructive models, can be misinterpreted as "over fitting." ISLs were not over fitted because a) they were not actually fitted at all: the values of the parameters after tuning are not thought to reflect some general physiological truth, and b) their complexity better reflected the situational adaptability of the referent liver. It is therefore not surprising that we could identify a parameterized NORMAL LIVER that validated, yet no straightforward strategy was found to successfully transform it, following the above three-step protocol, to yield a DISEASED LIVER that also validates.
Drug input and dosage time management. ISL experiments followed the same protocol used by (Hung et al., 2001 ) and (Cheung et al., 1996) . Sucrose was often co-administered with the drug of interest as an extravascular marker. Abnormalities in its outflow profile can indicate pathologies that otherwise might not be evident. We did the same. A bolus dose divided equally between SUCROSE and DILTIAZEM was injected into a simulated catheter that feeds into PV. COMPOUNDS were collected as they entered CV, simulating being collected by a fraction collector. Hung et al. used the sum of two inverse Gaussian density functions (requiring five-parameters) with a lag-time to simulate compound dilution and This article has not been copyedited and formatted. The final version may differ from this version. (Hung et al., 2001) , (Hung et al., 2002a,b) . They fitted the density function to averaged outflow profiles obtained following their standard experimental protocol when the liver was replaced by a shunt. They then used that fitted dosing function to correct outflow profiles prior to PK analysis. We obtained identically-shaped dosing curves using the three-parameter density function d(t). As done earlier , (Yan et al., 2008a,b,c) , we parameterized d(t) to provide quantitative control of COMPOUND input into PV and to simulate all influences on diltiazem in situ prior to reaching PV and after it exiting CV, before actual collection. Parameters a, b, and c determine the amplitude, location, and shape of the input density function; t is simulation time (TIME).
Inspection of the referent outflow profiles in Fig. 3 showed that diltiazem from the cirrhotic liver appeared sooner in the collected effluent, and its outflow profile peak occurred sooner. Because the catheters and perfusion apparatus were the same, we interpreted these changes as reflecting changes in large vein effects combined with differences in the more rapidly equilibrating, immediately accessible Only the artModel agent distinguishes between macro and micro actions. A micro cycle is called a step to distinguish it from a simulation cycle; each step maps to 0.25 seconds of wet-lab time. The artModel schedules macro actions before micro actions. Consequently, a bound DILTIAZEM can be released in one step; it can then re-bind in the next step before it is given an opportunity to move out of the CELL. All tracing algorithms operated each step to trace both micro and macro actions.
Iterative LOBULE refinement achieved validation of LIVER outflow profiles using a quantitative
Similarity Measure. Because of inter-and intraindividual variability, having a predicted pharmacokinetic profile be within a factor of two of the actual values has often been deemed acceptable (Fagerholm, 2007 Multi-scale traceability data facilitated unraveling the mechanistic differences regarding where and how NORMAL and DISEASED LIVERS interacted differently with COMPOUNDS and thus the causes underlying differences in their outflow profiles. It is infeasible to obtain comparable wet-lab data.
Nevertheless, we maintain that the relative tracing data has provided the current best approximation of This article has not been copyedited and formatted. The final version may differ from this version. 
Results
All results are from experiments on various ISLs. Assume, for the levels of abstraction used, that mappings A, B, and C in Fig. 2 (Hung et al., 2001 ), (Gaudio et al., 1997) . Our goal was to discover one plausible way in which spatiotemporal interactions between DILTIAZEM and LOBULAR components within validated NORMAL LIVERS could be changed so that the new outflow profile would validate against corresponding data from the CCl 4 -treated liver. The relative differences between the two differently parameterized LIVERS (NORMAL and DISEASED) could then stand as a hypothesis about the differences between the referent livers from the perspective of diltiazem (and sucrose) disposition.
Following the iterative refinement protocol, we first identified the NORMAL parameterization in We focused first on tuning seven of the nine parameters (Table 1) known to be sensitive to changes in referent drug physicochemical properties (PCPs) (Yan et al., 2008b,c 
JPET #142497
18 of 37 SUCROSE were used in both LIVERS, ISL2WetLabScaling and MetabolizeProb were held constant. To achieve the profile in Fig. 3B we ultimately changed eleven parameters. We did not choose a direction for parameter change based on preconceived ideas of how cirrhosis should be represented in a DISEASED LIVER. Rather, we allowed the iterative refinement protocol to guide parameter tuning. We were unable to achieve the most stringent SM for DISEASED LIVERS by tuning fewer parameters. Changes in those nine parameter values alone allowed us to achieve only the less stringent SM. We achieved the more stringent SMs by also changing slightly the mix of SS types used (SSTypeRatio) and the densities of CELLS (HEPATOCYTES) in Space C. In addition, SS circumference in all NORMAL LIVERS was tuned to 24 (grid spaces), whereas in the DISEASED LIVERS it was 25. That increase is consistent with the reported increased size of the Space of Disse in diseased livers (Gaudio et al., 1997) . SStypeRatio (Table 1 ; Fig.   4i ) controlled the ratio of direct (larger, shorter) and tortuous (thinner, longer) SS. NORMAL LIVERS used 95% direct, whereas DISEASED LIVERS used 99%. For each Monte Carlo LOBULE variant, each SS length was determined pseudo randomly to reflect uncertainties and biological variability. A set of five parameters specified their dimensional limits. Lengths for each SS were drawn randomly from a modified Gamma distribution .
The densities of CELLS in the ENDOTHELIAL and HEPATOCYTE layers (Spaces B and C) were controlled by separate parameters: ECDensity and HepDensity, respectively. The final, tuned value of ECDensity (0.65) was the same for the two LIVER types, whereas HepDensity was tuned to 0.70 in NORMAL and 0.65 in DISEASED LIVERS (Fig. 4E) . That corresponds to the observed, CCl 4 -induced rearrangement of hepatocyte quantitative ultrastructure (Hung et al., 2002b) .
It was essential to change all four of the parameters that control COMPOUND movement between Spaces A, B, and C ( Fig. 4A-C (Hung et al., 2002a) .
The number of BINDERS per CELL (Fig. 4D) needed to validate the DISEASED LIVER, relative to NORMAL, dropped from 95 to 65. BINDER properties also changed. In DISEASED LIVERS, relative to NORMAL, the probability of a BINDING event (Fig. 4F) occurring within a step (0.25 SECONDS) decreased from 0.5 to 0.35, whereas the binding duration (Fig. 4I) 
20 of 37 fibrosis.
The differences in Resident TIMES (Fig. 5A-D 4D) in DISEASED HEPATOCYTES. 4) For an unbound DILTIAZEM in a DISEASED HEPATOCYTE, the probability of binding to an ENZYME during any step was reduced from 0.5 to 0.35 (Fig. 4F ). (Fig. 4I) (Gaudio et al., 1997) .
5) SoluteBindingCycles
Despite differences in the parameter values that influence BINDING (Table 1 : BinderPerCell, SoluteBindingProb, and SoluteBindingCycles), the data in Fig. 6E and F show that the fraction of COMPOUNDS that was in the LOBULE at a particular TIME and was attached to a BINDER eventually reached a similar steady state ratio of about 0.8 in both NORMAL and DISEASED LOBULES. However, the relative fractions BOUND in ENDOTHELIAL and HEPATOCYTE layers were different.
Everything within hepatocytes capable of binding or sequestering diltiazem was conflated and represented using one BINDER type. Only a small subset of that material includes enzymes that metabolize diltiazem. Because of how events were scheduled, it is possible for a DILTIAZEM to be released toward the end of one simulation step and-by chance-be bound again to another BINDER in that same CELL before being given an opportunity to move out of the CELL.
DISEASE increased the TIME spent by DILTIAZEM within CELLS and changed the amount of
This article has not been copyedited and formatted. The final version may differ from this version. jpet.aspetjournals.org Downloaded from TIME spent bound. The differences in Resident Times, METABOLIC events, and Path Lengths traced in large part to the specific consequences of components encountered by DILTIAZEM at the lower levels ( Fig.   1 ). Four pairs of encounter records are presented as bar graphs in Fig. 7 . There was no corresponding SUCROSE data because SUCROSE did not enter CELLS. A record was kept of each DILTIAZEM location at each TIME step. The DOSE fraction that experienced an event (regardless of order) is indicated by bar height. Reflection on the similarities and differences for NORMAL and DISEASED LOBULES provides deeper insight into causes underlying features of the LIVER outflow profiles in Fig. 3 . For example, Fig.   7C shows that in a NORMAL LOBULE approximately 12.6% of the DOSE spent 2-to-3 SECONDS unbound in HEPATOCYTES before exiting the LOBULE, being METABOLIZED, or having the simulation terminate, whereas in a DISEASED LOBULE (Fig. 7D ) the corresponding value was 19.2%. That may seem counterintuitive initially, because there was more METABOLISM in NORMAL LIVERS. However, in DISEASED HEPATOCYTES, fewer ENZYME release events yielded a METABOLITE. Interestingly, the pattern was reversed for DILTIAZEMS spending 6-to-7 SECONDS in HEPATOCYTES. To demonstrate the nonlinearities of changes within SSs, the specific detailed changes for SS node #27 are provided in the supplemental data (see Supplemental Fig. S2 ).
To achieve the DISEASED LIVER validation in Fig. 3 , fewer BINDERS per DISEASED CELL (67 vs 97:
Fig . 4D ) were needed; in addition, the probability that a DILTIAZEM-BINDER encounter would result in a BIND event was reduced (Fig. 4F : 0.37 in DISEASED vs 0.7 in NORMAL ENDOTHELIAL CELLS and HEPATOCYTES), yet for DISEASED CELLS the effective duration of BINDING (Fig. 4I) increased by a factor of 2.77. The bar graphs in Fig. 7E and F show that these differences gave rise to very different BINDING The consequences of small parameter changes may not be evident. How sensitive are the characteristics of an outflow profile to changes in values of the key parameters in Fig. 4 ? Outflow profile sensitivity to parameter changes is discussed in : because all ISL mechanisms are networked, a change in ISL phenomena produced by a change in one parameter can often be offset by smaller, compensating changes in the values of several other parameters. Consequently, studies of sensitivity to individual parameters are less informative than are location changes in LOBULE parameter space. Individually, the parameter changes in Fig. 4 did not cause statistically distinguishable changes in outflow profiles. Nevertheless, someone experienced in observing different ISL outflow profiles may observe a perceptible change in outflow profile shape. In general, a 5% change in any one parameter will produce an imperceptible change in an outflow profile and no change in SM value. However, a 5% change in all parameters can cause a significant change in outflow profile. The changes in Fig. 4 averaged 38.5%.
Discussion
For the level of abstraction used, the two outflow profiles from NORMAL and DISEASED LIVERS matched referent profiles (Fig. 3) reasonably well. That evidence supports the idea that both mechanism and event level mappings in Fig. 2A may be reasonable. With additional rounds of iterative refinement and validation, ISLs may provide useful scientific predictions, as well as deeper insight into causal mechanisms within multiple levels. Similarity was achieved without having to use different SINUSOID networks for NORMAL versus DISEASED LIVERS. However, it is premature to assign biological significance to that lack of difference.
All NORMAL-to-DISEASED LIVER changes evolved without bias as a natural consequence of the iterative tuning protocol, yet all were consistent with cirrhosis-caused changes in the local environments encountered by diltiazem and sucrose. Taken together, the NORMAL-to-DISEASED changes retarded DILTIAZEM and SUCROSE movement between spaces, changing the Resident Time patterns (Fig. 5 ) and Path Lengths (Fig. 6 ). The coupling of those changes with altered BINDER and ENZYME attributes (Fig. 7) This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 6 ) and METABOLISM (Fig. 5 ).
The cited prior results supported component-to-component mappings between NORMAL LIVERS and normal livers (Mapping C in Fig. 2A ). Those similarities are reinforced by similarity of outflow profiles (Fig. 3) . The fact that drug PCPs can guide specification of PCP-sensitive NORMAL LIVER parameter values that validate for additional COMPOUNDS (Yan et al., 2008b,c) within analogues of cell cultures used in transport studies (Garmire et al., 2007) , (Lam and Hunt, 2008) , including hepatocytes (Sheikh-Bahae S and , and an in an analogue of the small intestine (Garmire and Hunt, 2008) .
This article has not been copyedited and formatted. The final version may differ from this version. Our strategy in developing and evolving synthetic analogues has been to iteratively expand the biologically relevant phenotype of the analogue so that it has an increasing variety of measurable attributes in common with referent systems. By so doing, we increase the variety of ways Mappings B and C in Fig. 2A can be concretized. For this study, there were four items on the targeted attribute list.
First, outflow profiles of DILTIAZEM from NORMAL LIVERS must also be similar (using a stringent SM) to the referent outflow profile. Second, outflow profiles of DILTIAZEM from DISEASED LIVERS must also be similar (using the same stringent SM) to the diltiazem outflow profile from a diseased liver. Third, the DISEASED LIVERS are achieved by simple transformation of NORMAL LIVER components and their
properties. Finally, that the NORMAL-to-DISEASED changes are consistent with histopathology data. To build confidence in Mappings B and C and the additional relationships illustrated in Fig. 2B , the set of targeted attributes for validation must be expanded. To achieve that objective, new wet-lab experiments will be helpful, but may not be essential: we can draw further on the abundance of relevant histopathology evidence available in the literature. For example, we could add two evidence-based attributes: that fibrosis retards access of small molecules to hepatocytes, and in cirrhotic livers, there are fewer fenestrae.
For those additions, the current DISEASED LIVERS would still validate because tuned values of both A2BJumpProb and B2CJumpProb in Fig. 3 are lower for the DISEASED LIVERS. Biologically, those lower values correspond to (predict) two differences between CCl 4 -treated relative to normal livers. 1) The probability of compounds like diltiazem entering the endothelial layer is reduced. 2) A compound within the endothelial layer will be retarded in passing through to the hepatocyte layer. For some other attributes, however, their inclusion in the list of targeted attributes would automatically falsify the current DISEASED LIVER. An example might be that the frequency of periportal interconnections between sinusoids is reduced in diseased livers. With that addition, we would need to seek a valid parameterization of a new DISEASED LIVER in which the SINUSOID network differs from the current one in measurable ways. With such future uses in mind, the ISL has been designed purposefully ) to make such change relatively easy.
This article has not been copyedited and formatted. The final version may differ from this version. (Höhme et al., 2007) .
Having independently validated NORMAL and DISEASED LIVERS allows one to explore plausible drug disposition consequences of intermediate levels of disease and even disease that is more advanced.
Because of individual differences in disease progression, conducting wet-lab experiments to document the former would be problematic, and the latter may be deemed unethical. By assuming disease progression corresponds to gradual change from NORMAL to DISEASED LIVER parameter values, we can simulate a liver that has progressed half way, for example, along the path to the currently documented disease state.
We can project further parameter changes to explore plausible consequences of more advanced level of disease. Corresponding explorations of intermediate and advanced disease states would be infeasible using traditional inductive mathematical models.
The methods and approach have been designed to enable the eventual development of horizontally and vertically integrated whole organism-whole patient-analogues. Once that goal has been achieved, it will be feasible to use in silico experimentation to anticipate PK properties of drugs in patients with liver disease.
This article has not been copyedited and formatted. The final version may differ from this version. In both cases, dosing started at t = 0. We re-used and tuned the previously validated dose input function , (Yan et al., 2008a) , equation 1. Its parameterization is listed in the supplemental data (see Supplemental Table S1 ). Table 1 , the changes in these nine contributed most to the differences between NORMAL and DISEASED LIVERS.
This article has not been copyedited and formatted. The final version may differ from this version. COMPOUNDS bound (within the LOBULE at the indicated TIME) at each TIME after experiment execution.
Top curve: total fraction bound. Bottom curve: fraction bound within HEPATOCYTES within Space C.
Middle curve: fraction bound within ENDOTHELIAL CELLS within Space B. This article has not been copyedited and formatted. The final version may differ from this version. 
